1-(6-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone | 1399849-64-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 1-(6-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone
• 英文别名: 3-Acetyl-6-Methyl-7-azaindole
• CAS: 1399849-64-9
• 化学式: C₁₀H₁₀N₂O
• 分子量: 174.202
• InChiKey: VSCNCIAQMRBEBC-UHFFFAOYSA-N

物化性质

• 密度：
  1.219±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 1-(6-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone 在 二异丙胺 、 三氟乙酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成
  参考文献：
  名称：

  Synthesis of novel 7-azaindole derivatives containing pyridin-3-ylmethyl dithiocarbamate moiety as potent PKM2 activators and PKM2 nucleus translocation inhibitors

  摘要：

  Multiple lines of evidence have indicated that pyruvate kinase M2 (PKM2) is upregulated in most cancer cells and it is increasingly recognized as a potential therapeutic target in oncology. In a continuation of our discovery of lead compound 5 and SAR study, the 7-azaindole moiety in compound 5 was systematically optimized. The results showed that compound 6f, which has a difluoroethyl substitution on the 7-azaindole ring, exhibited high PKM2 activation potency and anti-proliferation activities on A375 cell lines. In a xenograft mouse model, oral administration of compound 6f led to significant tumor regression without obvious toxicity. Further mechanistic studies revealed that 6f could influence the translocation of PKM2 into nucleus, as well as induction of apoptosis and autophagy of A375 cells. More importantly, compound 6f significantly inhibited migration of A375 cells in a concentration-dependent manner. Collectively, 6f may serve as a lead compound in the development of potent PKM2 activators for cancer therapy. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.03.003
• 作为产物：
  描述：

  1H-Pyrrolo[2,3-b]pyridine 7-Oxide 在 aluminum (III) chloride 、 四(三苯基膦)钯 、 四丁基硫酸氢铵 、 六甲基二硅氮烷 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 、 甲苯 为溶剂， 反应 80.5h， 生成 1-(6-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone
  参考文献：
  名称：

  Synthesis of novel 7-azaindole derivatives containing pyridin-3-ylmethyl dithiocarbamate moiety as potent PKM2 activators and PKM2 nucleus translocation inhibitors

  摘要：

  Multiple lines of evidence have indicated that pyruvate kinase M2 (PKM2) is upregulated in most cancer cells and it is increasingly recognized as a potential therapeutic target in oncology. In a continuation of our discovery of lead compound 5 and SAR study, the 7-azaindole moiety in compound 5 was systematically optimized. The results showed that compound 6f, which has a difluoroethyl substitution on the 7-azaindole ring, exhibited high PKM2 activation potency and anti-proliferation activities on A375 cell lines. In a xenograft mouse model, oral administration of compound 6f led to significant tumor regression without obvious toxicity. Further mechanistic studies revealed that 6f could influence the translocation of PKM2 into nucleus, as well as induction of apoptosis and autophagy of A375 cells. More importantly, compound 6f significantly inhibited migration of A375 cells in a concentration-dependent manner. Collectively, 6f may serve as a lead compound in the development of potent PKM2 activators for cancer therapy. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.03.003

文献信息

• NOVEL RENIN INHIBITOR
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US20150232459A1

  公开（公告）日：2015-08-20

  The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I] which is useful as a renin inhibitor. wherein R 1 is a cycloalkyl group or an alkyl, R 22 is an optionally substituted aryl and the like, R is a lower alkyl group, R 3 , R 4 , R 5 and R 6 are the same or different, and are a hydrogen atom, an optionally substituted carbamoyl, an optionally substituted alkyl, or alkoxycarbonyl, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种公式[I]的含氮饱和杂环化合物，其作为肾素抑制剂有用。 其中R1是环烷基或烷基， R22是可选择取代的芳基等， R是较低的烷基， R3、R4、R5和R6相同或不同，是氢原子、可选择取代的氨基甲酰基、可选择取代的烷基或烷氧羰基， 或其药用可接受盐。
• Nitrogen-containing saturated heterocyclic compound
  申请人：Iijima Toru

  公开号：US09278944B2

  公开（公告）日：2016-03-08

  The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]: wherein R1 is a cycloalkyl group and the like, R22 is an optionally substituted aryl and the like, R is a lower alkyl and the like, T is a carbonyl group, Z is —O— and the like, and R3 to R6 are the same or different and a hydrogen atom and the like; or a pharmaceutically acceptable salt, that is useful as a renin inhibitor.

  本发明提供一种含氮饱和杂环化合物，其化学式为[I]：其中，R1是环烷基等，R22是可选取代芳基等，R是较低烷基等，T是羰基等，Z是—O—等，R3至R6相同或不同，是氢原子等；或其药学上可接受的盐，其可用作肾素抑制剂。
• NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP2687518B1

  公开（公告）日：2017-11-01
• US9278944B2
  申请人：——

  公开号：US9278944B2

  公开（公告）日：2016-03-08
• US9556159B2
  申请人：——

  公开号：US9556159B2

  公开（公告）日：2017-01-31